|
TABLE OF CONTENTS 1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.3.2 GEOGRAPHIC SCOPE 17
1.3.3 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DATA 19
2.1.1 SECONDARY DATA 20
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY DATA 20
2.1.2.1 Key data from primary sources 21
2.1.2.2 Key industry insights 22
2.1.2.3 Breakdown of Primaries 22
2.2 MARKET SIZE ESTIMATION 23
2.2.1 BOTTOM-UP APPROACH 23
2.2.2 TOP-DOWN APPROACH 24
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 25
2.4 RESEARCH ASSUMPTIONS 26
2.4.1 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
3.1 INTRODUCTION 27
3.2 HISTORY, EVOLUTION, AND CURRENT SCENARIO 28
3.3 FUTURE OUTLOOK 29
3.4 CONCLUSION 31
4 PREMIUM INSIGHTS 32
4.1 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, 2014–2019 32
4.2 GLOBAL TRANSPLANT DIAGNOSTICS TECHNOLOGY MARKET, BY REGION (2014–2019) 33
4.3 TRANSPLANT DIAGNOSTIC PRODUCTS AND SERVICES MARKET, BY REGION (2014) 34
4.4 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY END USER (2014–2019) 35
4.5 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION (2014–2019) 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 38
5.2 MARKET SEGMENTATION 38
5.2.1 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY 38
5.2.2 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT 38
5.2.3 TRANSPLANT DIAGNOSTICS MARKET, BY END USER 39
5.2.4 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 39
5.3 MARKET DYNAMICS 39
5.3.1 DRIVERS 40
5.3.1.1 Rising number of solid organ, soft tissue, and stem cell transplantation procedures 40
5.3.1.2 Technological advancements in HLA typing 41
5.3.1.3 Growing geriatric population 42
5.3.2 RESTRAINTS 43
5.3.2.1 High cost of PCR and NGS instruments 43
5.3.2.2 Huge gap between number of organs donated and required annually 43
5.3.2.3 Limited medical reimbursements available for transplantation procedures 44
5.3.3 OPPORTUNITIES 44
5.3.3.1 Growing market penetration in emerging countries 44
5.3.3.2 Technological shift from serological assays to genome-based HLA profiling 45
6 INDUSTRY TRENDS 47
6.1 INTRODUCTION 47
6.2 VALUE CHAIN ANALYSIS 47
6.3 PORTER’S FIVE FORCES ANALYSIS 48
6.3.1 THREAT FROM NEW ENTRANTS 49
6.3.2 THREAT FROM SUBSTITUTES 50
6.3.3 BARGAINING POWER OF SUPPLIERS 50
6.3.4 BARGAINING POWER OF BUYERS 51
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 51
7 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY 52
7.1 INTRODUCTION 53
7.2 MOLECULAR ASSAYS 54
7.2.1 POLYMERASE CHAIN REACTION (PCR)-BASED 56
7.2.1.1 Sequence-specific Primer PCR (SSP-PCR) 56
7.2.1.2 Sequence-specific oligonucleotide PCR (SSO-PCR) 57
7.2.2 SEQUENCING-BASED ASSAYS 58
7.2.2.1 Sanger sequencing 59
7.2.2.2 Next-generation sequencing (NGS) 59
7.3 NON-MOLECULAR ASSAYS 60
7.3.1 SEROLOGICAL ASSAYS 62
7.3.2 MIXED LYMPHOCYTE CULTURE (MLC) ASSAYS 63
8 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 65
8.1 INTRODUCTION 66
8.2 REAGENTS AND CONSUMABLES 67
8.3 INSTRUMENTS 68
8.4 SOFTWARE AND SERVICES 69
9 TRANSPLANT DIAGNOSTICS MARKET, BY END USER 71
9.1 INTRODUCTION 72
9.2 HOSPITALS AND TRANSPLANT CENTERS 73
9.3 COMMERCIAL SERVICE PROVIDERS 74
9.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 75
10 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 77
10.1 INTRODUCTION 78
10.2 DIAGNOSTIC APPLICATIONS 79
10.3 RESEARCH APPLICATIONS 80
11 TRANSPLANT DIAGNOSTICS MARKET, BY REGION 81
11.1 INTRODUCTION 82
11.2 NORTH AMERICA 83
11.2.1 U.S. 84
11.2.2 CANADA 86
11.3 EUROPE 88
11.3.1 GERMANY 89
11.3.2 U.K. 91
11.3.3 FRANCE 93
11.3.4 REST OF EUROPE 94
11.4 ASIA-PACIFIC 97
11.4.1 JAPAN 98
11.4.2 CHINA 100
11.4.3 INDIA 102
11.4.4 REST OF ASIA-PACIFIC 104
11.5 REST OF THE WORLD 106
12 COMPETITIVE LANDSCAPE 108
12.1 OVERVIEW 108
12.2 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2013 108
12.3 COMPETITIVE SCENARIO 110
12.4 RECENT DEVELOPMENTS 111
12.4.1 MERGERS AND ACQUISITIONS 111
12.4.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 113
12.4.3 NEW PRODUCT LAUNCHES AND PRODUCT ENHANCEMENTS 114
12.4.4 GEOGRAPHICAL EXPANSION 115
12.4.5 OTHER DEVELOPMENTS 116
13 COMPANY PROFILES 117
(Overview, Financials, Products & Services, Strategy, & Developments)*
13.1 INTRODUCTION 117
13.2 THERMO FISHER SCIENTIFIC, INC. 120
13.3 IMMUCOR, INC. 125
13.4 OLERUP SSP AB 128
13.5 QIAGEN N.V. 130
13.6 BIO-RAD LABORATORIES, INC. 134
13.7 ABBOTT LABORATORIES, INC. 138
13.8 ILLUMINA, INC. 142
13.9 LINKAGE BIOSCIENCES, INC. 145
13.10 FUJIREBIO EUROPE N.V. 148
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
14 APPENDIX 149
14.1 INSIGHTS OF INDUSTRY EXPERTS 149
14.2 DISCUSSION GUIDE 150
14.3 COMPANY DEVELOPMENTS 154
14.3.1 THERMO FISHER SCIENTIFIC 154
14.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 155
14.5 AVAILABLE CUSTOMIZATIONS 155
14.6 RELATED REPORTS 156
The global transplant diagnostics market is poised to grow at a CAGR of 6.5% during 2014-2019, and is expected to reach a value of ~645.0 Million in 2019. Although the mature markets (such as the U.S., Germany, France, and U.K.) hold larger shares in the transplant diagnostics market, the Asia-Pacific region is expected to grow at the highest CAGR in the forecast period. The growth of the transplant diagnostics market is driven by factors such as growing geriatric population, coupled with an increasing population base for chronic disease patients, technological advancement in the field of HLA typing, increased public-private investments to develop innovative HLA testing products, rising number of solid organ, soft tissue, and stem cell-based transplantation procedures across the world. However, factors such as high cost of PCR and NGS instruments and limited medical reimbursement available for transplantation procedures are restraining the growth of this market. Huge gap between number of organs donated and organ donations required annually across the globe is posing a significant challenge for the growth of the transplant diagnostics market. In this report, the global transplant diagnostics market has been segmented on the basis of type of technology (molecular and non-molecular assay), type of product (instruments, reagents and consumables, and software and services), type of end users (hospitals and transplant centers, research laboratories and academic institutes, and commercial service providers) and type of application (diagnostic and research applications). The molecular assay technology segment accounted for the largest share of the global transplant diagnostics market in 2014, followed by the non-molecular assay technology market. Factors such as technological advancements in the field of HLA typing, rising adoption of HLA typing in research and medical diagnosis, benefits offered by robotics in lab automation, and increasing installation base of PCR and NGS instruments are driving the growth of transplant diagnostics market. Geographically, North America (comprising the U.S. and Canada) commands the largest share of the global transplant diagnostics market in 2014, followed by Europe. The transplant diagnostics market in the North America is primarily driven by factors such as increase in public and private funding for development of HLA typing technology, growing number of solid organ transplantation procedure, and continuous reduction in average cost of gene sequencing. However, financial constraints faced by market players are limiting the growth of the digital transplant diagnostics market in this region. The Asia-Pacific region is poised to grow at the highest CAGR during next five years, owing to factors such as increasing focus of global life science companies in emerging markets, growing public and private support to develop novel HLA typing technologies, and strengthening healthcare infrastructure across the region. The global transplant diagnostics market is moderately competitive with a various global as well as local market players. As of 2013, the global transplant diagnostics market was dominated by Thermo Fisher Scientific Inc. (U.S.), Immucor, Inc. (U.S.), Olerup Ssp Ab (Norway), Qiagen N.V. (Netherlands), Bio-Rad Laboratories Inc. (U.S.), and Abbott Laboratories Inc. (U.S.), which together accounted for ~89.0% of the market. New product launches, partnerships, agreements, and collaborations, and strategic acquisitions are the major strategies adopted by most of the market players to achieve growth in the global transplant diagnostics market. Reasons to Buy the Report: From an insight perspective, this research report has focused on various levels of analysis — industry analysis (industry trends and Porter’s five force model), market share analysis of top ten players, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high growth segments of the transplant diagnostics market, high-growth regions and their respective drivers, restraints, challenges, and opportunities. The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market, share. Firms purchasing the report could use any one or combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market share. The report provides insights on the following pointers: • Market Penetration: Comprehensive information on transplant diagnostics products offered by the top 10 players in the global transplant diagnostics market. The report analyzes the transplant diagnostics market by type of product, technology, end user, and application across key geographic region • Product Development/Innovation: Detailed insights on upcoming HLA typing technologies, research and development activities, and new product launches in the global transplant diagnostics market • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various transplant diagnostics products across key geographic region • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global transplant diagnostics market • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the global transplant diagnostics market
|
현재위치 : 
